etigilimab,nivolumab
mereo biopharmaceutical,bms,marker therapeutics
['activate trial']
future directions: 3 phase ii activate trials in mss crc, melanoma, and pancreatic look forward to updated results, correlative biomarkers, and upcoming trials in diverse tumor types 